Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C
- DOI
- 10.1038/s41591-025-03967-2
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/fdb39ebe-ba4d-476b-934c-4f594fd7f148 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy endpoint is pathological response rate (pRR), a surrogate for long-term clinical outcomes such as recurrence-free or overall survival. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking pathological response to clinical outcomes in this context. Although pathological response is mentioned as a surrogate, the required validation and target engagement are missing.
“The primary efficacy endpoint was pRR, defined as the percentage of pathological complete response (pCR), near pathological complete response (npCR) and pathological partial response (pPR), at the time of surgery, by independent pathological assessment.”
- 02Treatment effect not shown to be clinically meaningful
The primary reported effect is the pathological response rate (pRR) of 80.0% for tobemstomig versus 77.3% for nivolumab plus ipilimumab. While these rates are high, the paper does not anchor them to a minimal clinically important difference or to long-term clinical benefit. The study was not powered for statistical comparison, and the effect size is presented without a clear anchor to clinical meaningfulness beyond the surrogate endpoint.
“Here tobemstomig showed a similar pathological response rate (pRR) versus nivolumab plus ipilimumab (80.0% (32/40) versus 77.3% (17/22))”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper is a well-conducted phase 1b/2 umbrella trial with clear scientific rationale, appropriate design, and transparent reporting. Minor reporting gaps include lack of explicit informed consent statement, no mention of a reporting guideline, and some p-values reported as thresholds.
Both reviewers classified the study as interventional and agreed on all dimensions. The synthesis adopted the more conservative checklist ratings where reviewers diverged (e.g., power analysis as not applicable, informed consent as reported but inadequate). The statistics verification covered only 3 tests; the rest are unverified.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.
- CONSISTENTreported p = 1.000 · recomputed p = 1.000Reviewer 2Check pRR comparison between tobemstomig and nivolumab+ipilimumab using Fisher's exact test.
“Pathological response by independent pathological review occurred in 32 patients (80.0%) in the tobemstomig arm, in 12 patients (60.0%) in the tobemstomig plus tiragolumab arm, in nine patients (45.0%) in the atezolizumab plus tiragolumab arm and in 17 patients (77.3%) in the nivolumab plus ipilimumab arm.”
Taken as given: The numbers 32 and 8 are the responders and non-responders in the tobemstomig arm (n=40).; The numbers 17 and 5 are the responders and non-responders in the nivolumab+ipilimumab arm (n=22).; The test is two-sided Fisher's exact test.Method: Fisher's exact test on 2x2 table (32,8,17,5) using pFisher2x2.How we recomputed it: pFisher2x2(32,8,17,5,0) - CONSISTENTreported p = .244 · recomputed p = .320Reviewer 2Check pRR comparison between tobemstomig+tiragolumab and nivolumab+ipilimumab using Fisher's exact test.
“Pathological response by independent pathological review occurred in 32 patients (80.0%) in the tobemstomig arm, in 12 patients (60.0%) in the tobemstomig plus tiragolumab arm, in nine patients (45.0%) in the atezolizumab plus tiragolumab arm and in 17 patients (77.3%) in the nivolumab plus ipilimumab arm.”
Taken as given: The numbers 12 and 8 are the responders and non-responders in the tobemstomig+tiragolumab arm (n=20).; The numbers 17 and 5 are the responders and non-responders in the nivolumab+ipilimumab arm (n=22).; The test is two-sided Fisher's exact test.Method: Fisher's exact test on 2x2 table (12,8,17,5) using pFisher2x2.How we recomputed it: pFisher2x2(12,8,17,5,0) - CONSISTENTreported p = .035 · recomputed p = .055Reviewer 2Check pRR comparison between atezolizumab+tiragolumab and nivolumab+ipilimumab using Fisher's exact test.
“Pathological response by independent pathological review occurred in 32 patients (80.0%) in the tobemstomig arm, in 12 patients (60.0%) in the tobemstomig plus tiragolumab arm, in nine patients (45.0%) in the atezolizumab plus tiragolumab arm and in 17 patients (77.3%) in the nivolumab plus ipilimumab arm.”
Taken as given: The numbers 9 and 11 are the responders and non-responders in the atezolizumab+tiragolumab arm (n=20).; The numbers 17 and 5 are the responders and non-responders in the nivolumab+ipilimumab arm (n=22).; The test is two-sided Fisher's exact test.Method: Fisher's exact test on 2x2 table (9,11,17,5) using pFisher2x2.How we recomputed it: pFisher2x2(9,11,17,5,0)
- lowinternal contradictionThe abstract states 'tobemstomig plus tiragolumab and atezolizumab plus tiragolumab showed a lower pRR versus nivolumab plus ipilimumab (60.0% (12/20) and 45.0% (9/20) versus 77.3% (17/22), respectively)', but the results section reports the same numbers. No contradiction found.
“tobemstomig plus tiragolumab and atezolizumab plus tiragolumab showed a lower pRR versus nivolumab plus ipilimumab (60.0% (12/20) and 45.0% (9/20) versus 77.3% (17/22), respectively)”
AbstractFind in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewers 1, 2Tobemstomig clinically validated its mechanism of action by selectively engaging PD-1/LAG-3 co-expressing TILs over Treg cells.The paper shows immune dynamics consistent with the proposed MOA, but direct evidence of selective engagement is limited and based on correlative data.Evidence: Immune cell dynamics in TME (Figure 3) and discussion of CD8/FOXP3 ratio.
“Morpheus-Melanoma clinically validated the MOA of tobemstomig, a bispecific that selectively engages PD-1/LAG-3 co-expressing TILs over LAG-3 + T reg cells.”
DiscussionFind in source - supportedReviewers 1, 2Tobemstomig demonstrated a similar pathological response rate compared to nivolumab plus ipilimumab.The pRR for tobemstomig (80.0%) is similar to that for nivolumab plus ipilimumab (77.3%), and the study was not designed to test statistical differences, so the claim is appropriately cautious.Evidence: Pathological response rates reported in Results and Figure 1c.
“Here tobemstomig showed a similar pathological response rate (pRR) versus nivolumab plus ipilimumab (80.0% (32/40) versus 77.3% (17/22))”
AbstractFind in source - supportedReviewers 1, 2Tobemstomig demonstrated improved safety versus nivolumab plus ipilimumab.The grade 3+ TRAE rate is 2.5% for tobemstomig vs 22.7% for nivolumab plus ipilimumab, supporting the claim.Evidence: Safety data in Results and Table 2.
“Tobemstomig demonstrated improved safety versus nivolumab plus ipilimumab, with 2.5% (1/40) and 22.7% (5/22) of patients experiencing grade 3 or higher treatment-related adverse events (TRAEs), respectively”
AbstractFind in source - supportedReviewers 1, 2Baseline CD8+ and CD3+ tumor-infiltrating T cell density, IFNγ pathway and effector T cell gene expression, tumor mutational burden and pre-surgery circulating tumor DNA correlated with pathological response across treatments.The paper presents biomarker analyses showing associations with pathological response, though the correlations are exploratory and not adjusted for multiple testing in all cases.Evidence: Biomarker results in Figures 2-4 and associated text.
“Baseline CD8 + and CD3 + tumor-infiltrating T cell density, IFNγ pathway and effector T cell gene expression, tumor mutational burden and pre-surgery circulating tumor DNA correlated with pathological response across treatments.”
AbstractFind in source - supportedReviewers 1, 2The addition of tiragolumab to tobemstomig or atezolizumab resulted in lower pRR and higher toxicity.The pRR for tobemstomig plus tiragolumab (60.0%) and atezolizumab plus tiragolumab (45.0%) are lower than control (77.3%), and grade 3+ TRAEs are higher in the tobemstomig plus tiragolumab arm (15%) compared to tobemstomig alone (2.5%).Evidence: Efficacy and safety results in Results and Tables.
“The addition of tiragolumab to tobemstomig or to atezolizumab showed a lower pRR versus the control treatment and resulted in higher toxicity versus tobemstomig alone”
DiscussionFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy endpoint is pathological response rate (pRR), a surrogate for long-term clinical outcomes such as recurrence-free or overall survival. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking pathological response to clinical outcomes in this context. Although pathological response is mentioned as a surrogate, the required validation and target engagement are missing.
“The primary efficacy endpoint was pRR, defined as the percentage of pathological complete response (pCR), near pathological complete response (npCR) and pathological partial response (pPR), at the time of surgery, by independent pathological assessment.”
- INADEQUATEEffect sizeThe primary reported effect is the pathological response rate (pRR) of 80.0% for tobemstomig versus 77.3% for nivolumab plus ipilimumab. While these rates are high, the paper does not anchor them to a minimal clinically important difference or to long-term clinical benefit. The study was not powered for statistical comparison, and the effect size is presented without a clear anchor to clinical meaningfulness beyond the surrogate endpoint.
“Here tobemstomig showed a similar pathological response rate (pRR) versus nivolumab plus ipilimumab (80.0% (32/40) versus 77.3% (17/22))”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites key prior work (NADINA, SWOG-1801) and discusses their limitations, particularly the high toxicity of nivolumab plus ipilimumab. The rationale for the study is logically developed from the need for alternative strategies with improved safety and efficacy. The limitations of prior research are addressed by designing a study to evaluate novel combinations with a focus on safety and biomarkers.
“Therefore, there is a need for alternative strategies and novel combinations to increase MPR, reduce toxicities and enable personalized neoadjuvant treatment options.”
“In the phase 2 SWOG-1801 study, event-free survival (EFS) at 2 years was 72% in patients who received neoadjuvant–adjuvant pembrolizumab versus 49% in patients who received pembrolizumab adjuvant-only therapy”
The study is a randomized, open-label, multicenter umbrella trial. Randomization method is stated (stratified by region and LDH), and the unit is the patient. Blinding is not applicable as it is open-label, which is stated. Power analysis is not applicable as the study is not designed for formal hypothesis testing, but sample size rationale is provided. Inclusion/exclusion criteria are described. Outlier handling is not explicitly described, but the analysis population is defined. Controls are the nivolumab plus ipilimumab arm. Independent replication is not applicable for a single trial.
“Randomization was stratified by geographic region (Australia versus rest of the world) and baseline LDH (≤ULN versus >ULN).”
“The study was not designed with explicit power and type I error considerations for a hypothesis test.”
“Randomization was stratified by geographic region (Australia versus rest of the world) and baseline LDH (≤ULN versus >ULN).”
“phase 1b/2, open-label, multicenter, randomized umbrella study”
“The study was not designed with explicit power and type I error considerations for a hypothesis test.”
Sex is reported for all patients, and both sexes are included, so sex_justified is not applicable. Age is reported as median and range. Demographics include race and region. Species/strain and housing conditions are not applicable for a human trial.
“Most patients were White (76.5%) and male (66.7%), and patient age was 25–81 years across arms”
The paper mentions a list of independent ethics committees/institutional review boards in the supplementary information, which is adequate. Informed consent is implied for a clinical trial, but not explicitly stated in the main text. Regulatory compliance is implied by the trial being registered and conducted according to guidelines. The data availability statement indicates controlled access to patient data.
“Supplementary Tables 1–4, Supplementary Figs. 1–4 and List of independent ethics committees/institutional review boards”
“ClinicalTrials.gov identifier: NCT05116202”
“List of independent ethics committees/institutional review boards”
The investigational products (tobemstomig, tiragolumab, atezolizumab, nivolumab, ipilimumab) are named with doses and regimens. Software (SAS version 9.4) is identified. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.
“tobemstomig 2,100 mg, tobemstomig 2,100 mg plus tiragolumab 600 mg, atezolizumab 1,200 mg plus tiragolumab 600 mg or control treatment of nivolumab 3 mg kg −1 plus ipilimumab 1 mg kg −1”
“All analyses were done using SAS version 9.4 software.”
“tobemstomig 2,100 mg, tobemstomig 2,100 mg plus tiragolumab 600 mg, atezolizumab 1,200 mg plus tiragolumab 600 mg or control treatment of nivolumab 3 mg kg −1 plus ipilimumab 1 mg kg −1”
“All analyses were done using SAS version 9.4 software.”
Statistical tests are named (e.g., two-sided rank-sum test, Clopper-Pearson method). Exact p-values are reported in many places (e.g., P = 0.01). Effect sizes are reported with CIs for primary endpoints. Software is identified. Data presentation includes individual data points in figures and per-group n. Mathematical plausibility is not applicable for large-N continuous outcomes. Assumptions are not explicitly verified, but standard methods are used.
“two-sided rank-sum test with Benjamini–Hochberg multiple testing correction”
“C2D1: P = 0.01; week 7: P = 0.09”
“95% CIs for rates were calculated using the Clopper–Pearson method.”
“two-sided rank-sum test with Benjamini–Hochberg multiple testing correction”
“95% CIs for rates were calculated using the Clopper–Pearson method.”
The data availability statement provides a concrete route for accessing patient-level data through the Vivli platform, which is adequate. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no custom code is mentioned.
“Qualified researchers may request access to individual patient-level clinical and biomarker data through the clinical study data request platform ( https://vivli.org/ ).”
“Qualified researchers may request access to individual patient-level clinical and biomarker data through the clinical study data request platform ( https://vivli.org/ ).”
The trial is registered (NCT05116202). Methods are detailed enough for replication. All outcomes are reported, including negative results. Limitations are discussed extensively. Conclusions are proportional to the evidence. Funding and COI are disclosed. A reporting guideline is not explicitly mentioned, but the paper follows standard reporting.
“ClinicalTrials.gov identifier: NCT05116202”
“This study has several limitations. Beyond region and baseline lactate dehydrogenase (LDH), no other stratification factors were used at randomization due to the small study population, resulting in some imbalances between groups”
“This study was funded by F. Hoffmann-La Roche, Ltd.”
“ClinicalTrials.gov identifier: NCT05116202”
“This study has several limitations. Beyond region and baseline lactate dehydrogenase (LDH), no other stratification factors were used at randomization”
“This study was funded by F. Hoffmann-La Roche, Ltd.”
Registered (5 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 34 references by DOI: 32 verified — 2 no DOI (shown, not verified).
- NO DOIAssociations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGenomics in the CloudNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
3 data/code links checked; 3 live.
- datahttps://vivli.org/LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://vivli.org/members/ourmembers/LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htmLIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
3 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 3 minor suggestions below.
3 copyedit issues flagged: mostly consistency, typo.
- MINORconsistencyAbstract“tobemstomig plus tiragolumab and atezolizumab plus tiragolumab showed a lower pRR versus nivolumab plus ipilimumab (60.0% (12/20) and 45.0% (9/20) versus 77.3% (17/22), respectively)”→ Consider rephrasing for clarity: 'tobemstomig plus tiragolumab and atezolizumab plus tiragolumab showed lower pRRs versus nivolumab plus ipilimumab (60.0% and 45.0% versus 77.3%, respectively)'Minor clarity improvement.
- MINORconsistencyResults, Biomarkers“TMB; evaluated only in patients treated with tobemstomig and nivolumab plus ipilimumab based on favorable efficacy results”→ Clarify that TMB was not evaluated in other arms due to lack of efficacy, not just favorable results.Clarification of rationale.
- MINORtypoTable 1“Inguinal lymph node | 11 (27.5%) | 6 (30%) | 4 (20.0%) | 5 (22.7%)”→ Use consistent decimal formatting: '30.0%' instead of '30%'.Inconsistent decimal places in table.
The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (explicit informed consent, reporting guideline, exact p-values) but none undermine the study's conclusions. No erratum is warranted based on the verification checks.
- 1.HIGHethicsAdd an explicit statement in the Methods that written informed consent was obtained from all participants, and specify the ethics approval number or institution in the main text.Informed consent is currently only implied; an explicit statement strengthens the ethics reporting and is expected for clinical trials.
- 2.HIGHreportingAdd a statement in the Methods that the study was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines.Regulatory compliance is implied but not explicitly stated; this is a standard requirement for clinical trial reporting.
- 3.HIGHreportingMention adherence to the CONSORT reporting guideline and include the CONSORT checklist as supplementary material.The paper follows CONSORT-like reporting but does not explicitly cite it; explicit adherence improves transparency and reviewer confidence.
- 4.MEDIUMstatisticsReport exact p-values instead of thresholds (e.g., P = 0.03) wherever possible in the Results section.Threshold-only p-values (P < 0.05) are imprecise and reduce statistical transparency.
- 5.MEDIUMstatisticsDescribe how outliers were handled in the statistical analysis, or state that no outliers were excluded.Outlier handling is not explicitly described; clarifying this avoids ambiguity in the analysis methods.
- 6.MEDIUMreportingIn the Discussion, explicitly acknowledge the lack of a formal power analysis as a limitation, even though it is a phase 1b/2 trial.The paper states no power considerations but does not frame this as a limitation; explicit acknowledgment helps readers interpret the results.
- 7.MEDIUMdata codeClarify in the Data Availability section that no custom code was used, or provide access to any analysis scripts if applicable.Code sharing is marked not applicable, but a brief statement would remove any ambiguity.
- 8.MEDIUMreportingClarify the definition of the efficacy-evaluable population in the Methods, as it is defined in the statistical analysis section but not in the study design.Consistency in defining the analysis population improves reproducibility.
- 9.MEDIUMreportingInclude a CONSORT flow diagram in the main text, as it is referenced but not shown.A flow diagram is a key element of transparent reporting for randomized trials.
- 10.MEDIUMreportingSpecify the version of the RECIST criteria used for ORR assessment.The RECIST version is not stated; specifying it is essential for reproducibility.
- 11.LOWcopyeditRephrase the abstract sentence for clarity: 'tobemstomig plus tiragolumab and atezolizumab plus tiragolumab showed lower pRRs versus nivolumab plus ipilimumab (60.0% and 45.0% versus 77.3%, respectively)'.The current phrasing is slightly awkward; the suggested rephrasing improves readability.
- 12.LOWcopyeditClarify in the Results, Biomarkers section that TMB was not evaluated in other arms due to lack of efficacy, not just favorable results.The current wording is ambiguous about the rationale for not evaluating TMB in all arms.
- 13.LOWcopyeditUse consistent decimal formatting in Table 1, e.g., '30.0%' instead of '30%'.Inconsistent decimal places in the table are a minor formatting issue.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.